About OKYO Pharma

The Company recently delisted from AIM, as was approved by shareholders at a General Meeting held on 9 March 2018.

The Company is in the process of changing its name to OKYO Pharma Limited, migrating to Guernsey from the BVI, and adopting new constitutional documents compliant with Guernsey law, in place of the Company’s existing BVI law compliant constitutional documents.

The Board is actively involved in the appraisal of opportunities in the life sciences and biotechnology sector. The Board’s current intention is that on completion of an acquisition in this new sector, the Board will seek admission of the Company’s issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange plc.